We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.68B
AUM Growth
-$109M
Cap. Flow
-$70.1M
Cap. Flow %
-4.17%
Top 10 Hldgs %
48.34%
Holding
155
New
26
Increased
23
Reduced
13
Closed
37

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$26.4M
2
VTYX
Ventyx Biosciences
VTYX
+$20.8M
3
CBIO
Crescent Biopharma
CBIO
+$19.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$18.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$16.2M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$30.4M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.4M
3
ONC
BeOne Medicines Ltd
ONC
+$23.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.97%
2 Consumer Discretionary 5.18%
3 Financials 0.37%
4 Real Estate 0.31%
5 Technology 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVO icon
126
Evotec
EVO
$686M
– –
-1,149,425
Closed -$9.3M
IGMS
127
CALL
DELISTED
IGM Biosciences
IGMS
– –
-50,000
Closed -$851K
IMMP
128
Immutep
IMMP
$56.1M
– –
-1,000,000
Closed -$1.75M
INSM icon
129
Insmed
INSM
$22.4B
– –
-500,000
Closed -$9.99M
LYEL icon
130
Lyell Immunopharma
LYEL
$318M
– –
-35,000
Closed -$2.43M
LITS
131
Lite Strategy Inc
LITS
$32.4M
– –
-50,000
Closed -$244K
MIR icon
132
Mirion Technologies
MIR
$3.56B
– –
-500,000
Closed -$3.31M
MREO
133
Mereo BioPharma
MREO
$48.9M
– –
-1,500,000
Closed -$1.13M
OLMA icon
134
Olema Pharmaceuticals
OLMA
$977M
– –
-260,500
Closed -$638K
ORIC icon
135
Oric Pharmaceuticals
ORIC
$1.17B
– –
-400,000
Closed -$2.36M
OTLY
136
Oatly Group
OTLY
$476M
– –
-75,000
Closed -$2.61M
PANW icon
137
Palo Alto Networks
PANW
$256B
– –
-4,000
Closed -$279K
PRAX icon
138
Praxis Precision Medicines
PRAX
$8.11B
– –
-80,000
Closed -$2.86M
RXRX icon
139
Recursion Pharmaceuticals
RXRX
$1.58B
– –
-960,204
Closed -$7.4M
TIL icon
140
Instil Bio
TIL
$49M
– –
-22,500
Closed -$284K
TSLA icon
141
Tesla
TSLA
$1.18T
– –
-6,300
Closed -$776K
YMAB
142
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-400,000
Closed -$1.95M
ZYME icon
143
Zymeworks
ZYME
$1.62B
– –
-450,000
Closed -$3.54M
LENZ
144
LENZ Therapeutics
LENZ
$179M
– –
-100,000
Closed -$2.32M
ONC
145
CALL
BeOne Medicines Ltd
ONC
$33.9B
– –
-100,000
Closed -$22M
EXAI
146
DELISTED
Exscientia Plc American Depositary Shares
EXAI
– –
-550,000
Closed -$2.93M
GRTS
147
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-1,856,194
Closed -$6.4M
NEXI
148
DELISTED
NexImmune, Inc. Common Stock
NEXI
– –
-48,000
Closed -$292K
ORTX
149
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-180,386
Closed -$669K
MRTX
150
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-500,000
Closed -$22.7M
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2023 Portfolio in Review

As of Q1 2023, Artal Group held 155 positions worth $1.68B, down 6.1% from $1.79B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $70.1M in Q1 2023, closing 37 positions and reducing 13 holdings. Its most notable exit was BELLUS Health Inc., an estimated $30.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Ventyx Biosciences worth $17.9M.

  • Artal Group's largest Q1 2023 buy was Ventyx Biosciences: 535,812 shares worth $17.9M.
  • Artal Group added most to Revolution Medicines in Q1 2023, an estimated $26.4M increase.
  • Artal Group's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $28.4M.
  • Artal Group fully exited BELLUS Health Inc. in Q1 2023, selling an estimated $30.4M.
  • Artal Group's ten largest holdings make up 48% of its $1.68B portfolio in Q1 2023.
  • Artal Group opened 26 new positions and closed 37 in Q1 2023.
  • Artal Group's portfolio value fell 6.1% quarter-over-quarter to $1.68B.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.